Last reviewed · How we verify
Tab SRT2104 intermediate release — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Tab SRT2104 intermediate release (Tab SRT2104 intermediate release) — Sirtris, a GSK Company.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Tab SRT2104 intermediate release TARGET | Tab SRT2104 intermediate release | Sirtris, a GSK Company | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Tab SRT2104 intermediate release CI watch — RSS
- Tab SRT2104 intermediate release CI watch — Atom
- Tab SRT2104 intermediate release CI watch — JSON
- Tab SRT2104 intermediate release alone — RSS
Cite this brief
Drug Landscape (2026). Tab SRT2104 intermediate release — Competitive Intelligence Brief. https://druglandscape.com/ci/tab-srt2104-intermediate-release. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab